Phase III clinical trial protocols are rapidly integrating FDA-cleared wearable biometrics. By shifting patient data collection from periodic clinical visits to continuous remote telemetry, trial sponsors are observing higher participant retention rates.
Data Integrity and Scalability
Real-time telemetry provides broader datasets, capturing transient physiological changes that traditional monthly check-ups miss. Regulatory frameworks have matured, establishing standard validation criteria for continuous physiological endpoints.